Synthetic approaches to FDA approved drugs for asthma and COPD from 1969 to 2020

Respiratory infections resulting from pulmonary inflammation emerging as a leading cause of death worldwide. However, only twenty-seven new drugs were approved in the last five decades. In this review, we presented synthetic approaches for twenty-seven FDA-approved medications used to treat asthma and chronic obstructive pulmonary diseases (COPD), along with their mode of action.

Automated summary

Respiratory infections caused by pulmonary inflammation are a leading cause of death worldwide, yet only twenty-seven new drugs have been approved in the past fifty years. This review outlines synthetic approaches and mode of action for these FDA-approved medications used to treat asthma and COPD.